Fig. 4: Evaluation of the pharmacokinetics (PK) for PD-L1 degraders in vivo. | Nature Communications

Fig. 4: Evaluation of the pharmacokinetics (PK) for PD-L1 degraders in vivo.

From: Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins

Fig. 4: Evaluation of the pharmacokinetics (PK) for PD-L1 degraders in vivo.The alternative text for this image may have been generated using AI.

a Blot intensity of rat IgG in the plasma of C57BL/6 mice treated with Ab3, Ab3-FA-12x, Ab3-FA-25x at different time points (2.5 mg/kg via IP injection). Data are presented as mean ± SD, n = 4. b Concentration of Ab3-FA-25x in C57BL/6 mice bearing B16F10 tumor at different time points (2.5 mg/kg via IP injection) Data are presented as mean ± SD, n = 3. (12x and 25x: 12 or 25 molar equivalents of DBCO-NHS ester in the first step; 25 equivalents of folate-azide were used in the second step). N indicates mice. Source data are provided as a Source Data file.

Back to article page